Skip to main content

ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference. The presentation is scheduled for 8:30 a.m. ET on August 8, 2018.

A webcast of the presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts:

INVESTOR RELATIONS CONTACT
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
MEDIA CONTACT
ImmunoGen, Inc.
Courtney O’Konek, 781-895-0600
courtney.okonek@immunogen.com
or
FTI Consulting
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.